Tesamorelin/Ipamorelin (3:1 ratio, 6 mg tesamorelin + 2 mg Ipamorelin, 8 mg total) is a GHRH-dominant growth hormone secretagogue blend optimized for investigating primary GHRH-mediated GH secretion with GHS-R1a adjunctive activation. This formulation supports preclinical research emphasizing GHRH receptor signaling dominance while incorporating GHS-R pathway contribution, enabling study of weighted dual-pathway GH axis regulation.

Chemical Specifications:

• Chemical Name: Tesamorelin (GHRH analog) + Ipamorelin (GHS-R agonist)
• Molecular Formula: Combined C166H265N47O45S + C38H50N8O5 (approximate)
• Molecular Weight: Combined ~3450 g/mol (approximate)
• Compound Class: GHRH-dominant dual secretagogue blend (3:1 ratio)

The 3:1 tesamorelin:Ipamorelin ratio emphasizes GHRH pathway activity while providing secondary GHS-R1a stimulation. This weighted formulation models research scenarios where GHRH signaling predominates in GH axis activation, with Ipamorelin providing complementary pathway contribution.

Research Applications:

• Investigating GHRH-primary GH secretion with secondary GHS-R contribution
• Characterizing ratio-dependent effects on GH secretion dynamics
• Modeling GHRH-dominant pathway activation in pituitary studies
• Examining weighted dual-pathway signaling in GH regulation research
• Studying GH axis function in scenarios of GHRH abundance and GHS-R augmentation

Storage and Handling:

• Store at -20°C or -80°C in sealed, inert peptide containers
• Maintain protection from moisture and oxidative exposure
• Reconstitute using sterile peptide buffers with appropriate pH
• Keep frozen until use to preserve blend component integrity

Product Specifications:

• Purity: >97% HPLC combined purity
• Form: Lyophilized powder blend
• Appearance: White to off-white freeze-dried powder
• Quantity: 8 mg total (6 mg tesamorelin + 2 mg Ipamorelin)

FOR RESEARCH USE ONLY. Not intended for human consumption or clinical use. All products are sold strictly for laboratory, educational, and scientific research purposes.